Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

Table 3 Allred scores of Ki67 biomarker immunohistochemistry results in ER-β-negative and ER-β-positive cases

Ki67	Anastrozole (A)		Placebo (P)		Tamoxifen (T)
	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
ER- β-negative
Mean ± SD	4.2 ± 1.9	3.5 ± 2.8	2.3 ± 1.4	2.2 ± 1.7	4.6 ± 1.9	3.4 ± 2.7
Median (minimum–maximum)	4 (2–8)	2 (0–8)	2 (0–4)	2 (0–5)	4 (2–7)	3 (0–7)
Total (n)	11	11	12	12	5	5
ER- β-positive
Mean ± SD	4.5 ± 2	3.2 ± 2.1*	3.6 ± 1.8	4 ± 1.6	3.8 ± 1.8	2.9 ± 2.1**
Median (minimum–maximum)	4 (0–7)	2 (0–7)	4 (0–6)	4 (2–6)	4 (0–6)	3 (0–7)
Total (n)	13	13	16	16	18	18

SD: standard deviation.
ER-β-negative: ANOVA with repeated measures: group (p = 0.071), treatment (p = 0.084) and group × treatment (p = 0.446).
ER-β-positive: ANOVA with repeated measures: group (p = 0.726), treatment (p = 0.036) and group × treatment (p = 0.032).
Bonferroni multiple comparison test for ER-β-positive analysis: group A (pre- × post-treatment: p = 0.014*), group P (pre- × post-treatment: p = 0.113) and group T (pre- × post-treatment: p = 0.046**).

ISSN: 1471-2407